Technical Analysis for ORGS - Orgenesis Inc.

Grade Last Price % Change Price Change
F 0.52 1.18% 0.01
ORGS closed up 0.63 percent on Thursday, April 18, 2024, on 9 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 8
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Boomer Buy Setup Bullish Swing Setup 0.76%
Calm After Storm Range Contraction 0.76%
NR7 Range Contraction 0.76%
Narrow Range Bar Range Contraction 0.76%
Inside Day Range Contraction 0.76%
Wide Bands Range Expansion 0.76%
Up 3 Days in a Row Strength 0.76%
Up 4 Days in a Row Strength 0.76%
Calm After Storm Range Contraction 1.40%
Narrow Range Bar Range Contraction 1.40%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 4 hours ago
Outside Day about 4 hours ago
Down 3% about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
Down 2 % about 4 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Orgenesis Inc. Description

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Development Diabetes Stem Cell Cell Therapy Insulin Endocrine System Regenerative Medicine Hormones Contract Manufacturing Peptide Hormones Contract Manufacturing Services Type I Diabetes Assay Development Services Diabetes Mellitus Type 1 Medicinal Product Medicinal Products

Is ORGS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.49
52 Week Low 0.25
Average Volume 287,136
200-Day Moving Average 0.68
50-Day Moving Average 0.62
20-Day Moving Average 0.62
10-Day Moving Average 0.51
Average True Range 0.10
RSI (14) 42.53
ADX 31.86
+DI 28.77
-DI 19.43
Chandelier Exit (Long, 3 ATRs) 0.61
Chandelier Exit (Short, 3 ATRs) 0.61
Upper Bollinger Bands 0.95
Lower Bollinger Band 0.28
Percent B (%b) 0.35
BandWidth 109.67
MACD Line -0.05
MACD Signal Line -0.04
MACD Histogram -0.0121
Fundamentals Value
Market Cap 16.32 Million
Num Shares 31.9 Million
EPS -0.91
Price-to-Earnings (P/E) Ratio -0.56
Price-to-Sales 0.34
Price-to-Book 0.77
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.53
Resistance 3 (R3) 0.53 0.52 0.53
Resistance 2 (R2) 0.52 0.52 0.52 0.53
Resistance 1 (R1) 0.52 0.51 0.52 0.52 0.53
Pivot Point 0.51 0.51 0.51 0.51 0.51
Support 1 (S1) 0.50 0.50 0.51 0.51 0.50
Support 2 (S2) 0.50 0.50 0.50 0.50
Support 3 (S3) 0.49 0.50 0.50
Support 4 (S4) 0.49